NEW YORK — Cancer diagnostics developer Syantra said Wednesday that it has raised C$4.9 million (US$3.6 million) in a Series A-1 financing round.

纽约-癌症诊断开发商Syantra周三表示，在a-1系列融资中，已筹集490万加元（360万美元）。

The round included unnamed individuals associated with CG Wealth Management, as well as certain existing investors, the Calgary, Canada-based company said.

总部位于加拿大卡尔加里的CG财富管理公司表示，此次交易包括与CG财富管理相关的未透露姓名的个人，以及某些现有投资者。

Syantra, a spinout of the University of Calgary, has developed a liquid biopsy test that measures a panel of messenger RNA biomarkers in blood using real-time PCR and machine learning for the early detection of breast cancer. Dubbed the Syantra DX Breast Cancer Test, the assay received CE-IVD marking in mid-2023 and is currently being evaluated in a Cornell University-led clinical trial supported by $2.4 million in US Department of Defense funding..

卡尔加里大学的分支机构Syantra开发了一种液体活检测试，该测试使用实时PCR和机器学习来测量血液中的一组信使RNA生物标志物，以早期检测乳腺癌。该试验被称为Syantra DX乳腺癌试验，于2023年年中接受了CE-IVD标记，目前正在康奈尔大学领导的临床试验中进行评估，该试验得到了美国国防部240万美元的资助。。

Syantra said it will use the Series A-1 funding to fast-track the clinical validation and commercialization of the breast cancer test.

Syantra表示，它将利用A-1系列资金快速推进乳腺癌检测的临床验证和商业化。

'This influx of support will empower Syantra to focus on the science that drives us forward, enabling the team to execute ongoing clinical studies and other efforts prior to ramping up commercialization in 2025,' Syantra CEO Rob Lozuk said in a statement.

Syantra首席执行官罗布·洛祖克（RobLozuk）在一份声明中说：“大量的支持将使Syantra能够专注于推动我们前进的科学，使团队能够在2025年扩大商业化之前进行正在进行的临床研究和其他努力。”。